Modality
Cell Therapy
MOA
CAR-T BCMA
Target
LAG-3
Pathway
Epigenetic
Atopic Derm
Development Pipeline
Preclinical
~Jan 2021
→ ~Apr 2022
Phase 1
~Jul 2022
→ ~Oct 2023
Phase 2
~Jan 2024
→ ~Apr 2025
Phase 3
Jul 2025
→ Feb 2027
Phase 3Current
NCT04232569
1,273 pts·Atopic Derm
2025-07→2027-02·Terminated
1,273 total pts1 indication
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2027-02-0310mo awayPh3 Readout· Atopic Derm
Trial Timeline
Q3Q42026Q2Q3Q42027
P3
Termina…
Catalysts
Ph3 Readout
2027-02-03 · 10mo away
Atopic Derm
Terminated|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04232569 | Phase 3 | Atopic Derm | Terminated | 1273 | ORR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Voxacilimab | Pfizer | Phase 2 | TYK2 | |
| ABB-3060 | AbbVie | Phase 2 | LAG-3 | |
| NVO-9087 | Novo Nordisk | Phase 1/2 | Tau | |
| Polazasiran | Amgen | Phase 2 | LAG-3 | |
| Fixazanubrutinib | Amgen | Phase 2 | PI3Kα | |
| REG-8074 | Regeneron | Phase 2/3 | KRASG12C | |
| ALN-6288 | Alnylam | Approved | LAG-3 | |
| Sovarelsin | Alnylam | Phase 2/3 | LAG-3 | |
| JAZ-8729 | Jazz Pharma | Phase 2/3 | FcRn | |
| ACA-2691 | Acadia Pharma | Phase 3 | BCMA |